Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Cited by (1,051)

Items 501–600 of 1,051

1. Anaphylatoxin C5a Creates a Favorable Microenvironment for Lung Cancer Progression
   Leticia P. Corrales, Daniel Ajona, Stavros Rafail, Juan José Lasarte, José Ignacio Riezu‐Boj, John D. Lambris, Ana Rouzaut, Maria Jose Pajares, Luis M. Montuenga, Rubén Pı́o · 2012 · The Journal of Immunology
2. Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor
   Liting Guo, Haijun Zhang, Baoan Chen · 2017 · Journal of Cancer
3. Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy
   Weiqiang Zhou, Shanchun Guo, Mingli Liu, Matthew E. Burow, Guangdi Wang · 2017 · Current Medicinal Chemistry
4. Interleukin‐6/ <scp>STAT</scp> 3 signaling as a promising target to improve the efficacy of cancer immunotherapy
   Kitamura, Hidemitsu, Ohno, Yosuke, Toyoshima, Yujiro, Ohtake, Junya, Homma, Shigenori, Kawamura, Hideki, Takahashi, Norihiko, Taketomi, Akinobu · 2017 · Cancer Science
5. Palmitoylation stabilizes PD-L1 to promote breast tumor growth
   Yi Yang, Jung-Mao Hsu, Linlin Sun, Li-Chuan Chan, Chia‐Wei Li, Jennifer L. Hsu, Yongkun Wei, Weiya Xia, Junwei Hou, Yufan Qiu et al. · 2018 · Cell Research
6. Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo
   Satoshi Yasuda, Masayuki Sho, I Yamato, Hitoshi Yoshiji, Koji Wakatsuki, Satoshi Nishiwada, Hideo Yagita∥, Y. Nakajima · 2013 · Clinical & Experimental Immunology
7. Loss of P53 Function Activates JAK2–STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival
   Sonja M. Wörmann, Liang Song, Jiaoyu Ai, Kalliope Nina Diakopoulos, Magdalena U. Kurkowski, Kıvanç Görgülü, Dietrich Alexander Ruess, Andrew D. Campbell, Claudio Doglioni, Duncan Ian Jodrell et al. · 2016 · Gastroenterology
8. Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer
   Benjamin Frank Goeppert, Lena Frauenschuh, Manuela Zucknick, Albrecht Stenzinger, Mindaugas Andrulis, Frederick Klauschen, Korinna Joehrens, Arne Warth, Marcus Renner, Arianeb Mehrabi et al. · 2013 · British Journal of Cancer
9. The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer
   Freed-Pastor, William A., Lambert, Laurens J., Ely, Zackery A., Pattada, Nimisha B., Bhutkar, Arjun, Eng, George, Mercer, Kim L., Garcia, Ana P., Lin, Lin, Rideout, William M. et al. · 2021 · Cancer Cell
10. Diagnosis and Molecular Classification of Lung Cancer
    Jaime Rodriguez‐Canales, Edwin Roger Parra-Cuentas, Ignacio Ivan Wistuba · 2016 · Cancer treatment and research
11. Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells
    Annie A. Wu, Virginia E. Drake, Huai-Shiuan Huang, ShihChi Chiu, Lei Zheng · 2015 · OncoImmunology
12. PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer
    Song, Minmin, Chen, Defeng, Lu, Biyan, Wang, Chenliang, Zhang, Junxiao, Huang, Lanlan, Wang, Xiaoyan, Timmons, Christine L., Hu, Jun, Liu, Bindong et al. · 2013 · PLoS ONE
13. Combined Magnetic Hyperthermia and Immune Therapy for Primary and Metastatic Tumor Treatments
    Jiong Pan, Ping Hu, Yuedong Guo, Junnian Hao, Dalong Ni, Yingying Xu, Qunqun Bao, Heliang Yao, Chenyang Wei, Qingsheng Wu et al. · 2020 · ACS Nano
14. Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
    Michael Hölzel, Anton Bovier, Thomas Tüting · 2013 · Nature reviews. Cancer
15. PD1 signal transduction pathways in T cells
    Hugo Arasanz, María Gato, Miren Zuazo, María Ibáñez-Vea, Karine Breckpot, Grazyna T. Kochan, David Escors · 2017 · Oncotarget
16. Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma
    Lisa Zimmer, Julia Vaübel, Peter Mohr, Axel Hauschild, Jochen Sven Utikal, Jan Christoph Simon, Claus Garbe, Rudolf Alexander Herbst, Alexander Enk, Eckhart Kämpgen et al. · 2015 · PLoS ONE
17. Programmed death-1 pathway in cancer and autoimmunity
    Ariel Pedoeem, Inbar Azoulay‐Alfaguter, Marianne Strazza, Gregg J. Silverman, Adam Mor · 2014 · Clinical Immunology
18. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
    Deborah A. Knight, Shin Foong Ngiow, Ming Li, Tiffany J. Parmenter, Stephen Mok, Ashley A. Cass, Nicole M. Haynes, Kathryn M. Kinross, Hideo Yagita∥, Richard Chikara Koya et al. · 2013 · Journal of Clinical Investigation · Retracted
19. Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses
    Xuanming Yang, Xunmin Zhang, May Lynne Fu, Ralph R. Weichselbaum, Thomas F. Gajewski, Yajun Guo, Yang‐Xin Fu · 2014 · Cancer Cell
20. Driving gene-engineered T cell immunotherapy of cancer
    Laura A Johnson, Carl H. June · 2016 · Cell Research
21. LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes
    Yayi He, Hui Yu, Leslie M. Rozeboom, Christopher J. Rivard, Kim E. Ellison, Rafał Dziadziuszko, Kenichi Suda, Shengxiang Ren, Chunyan Wu, Likun Hou et al. · 2017 · Journal of Thoracic Oncology
22. Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy
    Lee, Nayoung, Zakka, Labib R., Mihm, Martin C., Schatton, Tobias · 2016 · Pathology
23. Advances in targeting cell surface signalling molecules for immune modulation
    Sheng Yao, Yuwen Zhu, Lieping Chen · 2013 · Nature Reviews Drug Discovery
24. Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect
    David J. DiLillo, Jeffrey V. Ravetch · 2015 · Cell
25. Adoptive Immunotherapy for Cancer or Viruses
    Marcela Valderrama Maus, Joseph A. Fraietta, Bruce L. Levine, Michael D. Kalos, Yangbing Zhao, Carl H. June · 2014 · Annual Review of Immunology
26. Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma
    Gaixia He, Henghui Zhang, Jinxue Zhou, Beibei Wang, Yanhui Chen, Yaxian Kong, Xingwang Xie, Xueyan Wang, Ran Fei, Lai Wei et al. · 2015 · Journal of Experimental & Clinical Cancer Research
27. The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion
    Chunwan Lu, Amy V. Paschall, Huidong Shi, Natasha M. Savage, Jennifer L. Waller, Maria Eugenia Sabbatini, Nicholas H. Oberlies, Cedric J. Pearce, Kebin Liu · 2016 · JNCI Journal of the National Cancer Institute
28. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies
    Vincent Sibaud, Nicolás Meyer, Laurence Lamant, Émmanuelle Vigarios, Julien Mazières, Jean Pierre Delord · 2016 · Current Opinion in Oncology
29. CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response
    Daniele Biasci, Martin Smoragiewicz, Claire M. Connell, Zhikai Wang, Ya Gao, James E. D. Thaventhiran, Bristi Basu, Łukasz Magiera, Timothy Isaac Johnson, Lisa Bax et al. · 2020 · Proceedings of the National Academy of Sciences
30. Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors
    Gaurav Bajaj, Xueyan Wang, S Agrawal, Manish Gupta, Amit Roy, Y Feng · 2016 · CPT Pharmacometrics & Systems Pharmacology
31. Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition
    David A. Fabrizio, Thomas J. George, Richard Francis Dunne, Garrett Michael Frampton, James X. Sun, Kyle A. Gowen, Mark Kennedy, Joel R. Greenbowe, Alexa Betzig Schrock, Aram F. Hezel et al. · 2018 · Journal of Gastrointestinal Oncology
32. The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer
    Yu Fujita, Shigehiro Yagishita, Keitaro Hagiwara, Yusuke Yoshioka, Nobuyoshi Kosaka, Fumitaka Takeshita, Tomohiro Fujiwara, Koji Tsuta, Hiroshi Nokihara, Tomohide Tamura et al. · 2015 · Molecular Therapy
33. Does the Immune System Naturally Protect Against Cancer?
    Alexandre Corthay · 2014 · Frontiers in Immunology
34. Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors
    David Makarious, K. Horwood, Jermaine Ian George Coward · 2017 · European Journal of Cancer
35. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial
    Pant, Shubham, Wainberg, Zev A., Weekes, Colin D., Furqan, Muhammad, Kasi, Pashtoon M., Devoe, Craig E., Leal, Alexis D., Chung, Vincent, Basturk, Olca, VanWyk, Haley et al. · 2024 · Nature Medicine
36. Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy
    Xiaohong Wang, Jonathan E. Schoenhals, Ailin Li, David R. Valdecanas, Huiping Ye, Fenglin Zang, Chad Z. Tang, Ming Tang, Chang‐Gong Liu, Xiuping Liu et al. · 2016 · Cancer Research
37. Novel immunotherapies in lymphoid malignancies
    Connie Lee Batlevi, Eri Matsuki, Renier J. Brentjens, Anas Younes · 2015 · Nature Reviews Clinical Oncology
38. Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma
    Geoffrey Thomas Gibney, Ragini Reiney Kudchadkar, Ronald C. DeConti, Melissa S. Thebeau, Maria P. Czupryn, Leticia F. Tetteh, Cabell E. Eysmans, Allison D. Richards, Michael J. Schell, Kate J. Fisher et al. · 2014 · Clinical Cancer Research
39. Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
    Zachary Aaron Cooper, Vikram R. Juneja, Peter T. Sage, Dennie Tompers Frederick, Adriano Piris, Devarati Mitra, Jennifer A. Lo, Frank Stephen Hodi, Gordon James Freeman, Marcus Bosenberg et al. · 2014 · Cancer Immunology Research
40. PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis
    Bernd H. Zinselmeyer, Sara Heydari, Catarina Sacristán, Debasis Nayak, Michael Cammer, Jasmin Herz, Xiaoxiao Cheng, Simon J. Davis, Michael Loran Dustin, Dorian B. McGavern · 2013 · The Journal of Experimental Medicine
41. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients
    Marius Ilié, Véronique Hofman, Manfred Dietel, Jean‐Charles Soria, Paul M Hofman · 2016 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
42. First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting
    Neeta D. Pandit-Taskar, Michael Andrew Postow, Matthew David Hellmann, James J. Harding, Christopher Andrew Barker, Joseph A. O’Donoghue, Martha Ziolkowska, Shutian Ruan, Serge K. Lyashchenko, Frank Yung-Chin Tsai et al. · 2019 · Journal of Nuclear Medicine
43. Biomarkers for immunotherapy response in head and neck cancer
    Niki Gavrielatou, S Doumas, Panagiota Economopoulou, Periklis G. Foukas, Amanda Psyrri · 2020 · Cancer Treatment Reviews
44. Current Advances in Photodynamic Therapy (PDT) and the Future Potential of PDT-Combinatorial Cancer Therapies
    Niuska Alvarez, Ana Sevilla · 2024 · International Journal of Molecular Sciences
45. Metastatic recurrence in colorectal cancer arises from residual EMP1+ cells
    Cañellas-Socias, Adrià, Cortina, Carme, Hernando-Momblona, Xavier, Palomo-Ponce, Sergio, Mulholland, Eoghan J., Turon, Gemma, Mateo, Lidia, Conti, Sefora, Roman, Olga, Sevillano, Marta et al. · 2022 · Nature
46. 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity
    Todd Bartkowiak, Michael A. Curran · 2015 · Frontiers in Oncology
47. Immune Cell–Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation
    Tobias Bald, Jennifer Landsberg, Dorys Lopez-Ramos, Marcel Renn, Nicole Glodde, Philipp Jansen, Evelyn Gaffal, Julia Steitz, Rene Hany Tolba, Ulrich Kalinke et al. · 2014 · Cancer Discovery
48. Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy
    Xiao Ling Zhao, Keni Yang, Ruifang Zhao, Tianjiao Ji, Xiuchao Wang, Xiao Yang, Yinlong Zhang, Keman Cheng, Shaoli Liu, Jihui Hao et al. · 2016 · Biomaterials
49. The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis
    A. Wang, H.Y. Wang, Yi Liu, M.C. Zhao, Hongwei Zhang, Zhonghua Lu, Y.C. Fang, Xuanlong Chen, G.T. Liu · 2015 · European Journal of Surgical Oncology
50. Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559)*
    Richard S. Hotchkiss, Elizabeth Colston, Sachin P. Yende, Derek C. Angus, Lyle L. Moldawer, Elliott D. Crouser, Greg S. Martin, Craig M. Coopersmith, Scott C. Brakenridge, Florian Mayr et al. · 2019 · Critical Care Medicine
51. Host tissue determinants of tumour immunity
    Hélène Salmon, Romain Remark, Sacha Gnjatic, Miriam Mérad · 2019 · Nature reviews. Cancer
52. An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases
    Yang Liu, William N. Crowe, Lulu Wang, Yong Lu, William Jeffrey Petty, Amyn A. Habib, Dawen Zhao · 2019 · Nature Communications
53. PD-1 marks dysfunctional regulatory T cells in malignant gliomas
    D. E. Lowther, Brittany A. Goods, Liliana E. Lucca, B. Lerner, K. Raddassi, D. van Dijk, Amanda L. Hernandez, Xiang-Guo Duan, M. Gunel, V. Coric et al. · 2016 · JCI Insight
54. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8+ T Cells and Features of Hepatocellular Carcinoma
    Hyung‐Don Kim, Gi‐Won Song, Seongyeol Park, Min Hwan Kim, Min Hwan Kim, Hyo Jeong Kang, Changhoon Yoo, Kyung Hwan Kim, Kyung Hwan Kim, Su-Kyeong Eo et al. · 2018 · Gastroenterology
55. Metallodrugs in cancer nanomedicine
    Peña, Quim, Wang, Alec, Zaremba, Orysia, Shi, Yang, Scheeren, Hans W., Metselaar, Josbert M., Kiessling, Fabian, Pallares, Roger M., Wuttke, Stefan, Lammers, Twan · 2022 · Chemical Society Reviews
56. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study
    Minoru Miyashita, Hironobu Sasano, Kentaro Tamaki, Hisashi Hirakawa, Yayoi Takahashi, Saki Nakagawa, Gou Watanabe, Hiroshi Tada, Akihiko Suzuki, Noriaki Ohuchi et al. · 2015 · Breast Cancer Research
57. PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis
    Tim Wartewig, Zsuzsanna Kurgyis, Selina Jessica Keppler, Konstanze Pechloff, Erik Hameister, Rupert Öllinger, Roman Maresch, Thorsten Buch, Katja Steiger, Christof Winter et al. · 2017 · Nature
58. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models
    Wang, Zebin, Sun, Kaiming, Xiao, Yonghong, Feng, Bin, Mikule, Keith, Ma, XiaoYan, Feng, Ningping, Vellano, Christopher P., Federico, Lorenzo, Marszalek, Joseph R. et al. · 2019 · Scientific Reports
59. DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application
    Chunhong Hu, Xiaohan Liu, Yue Zeng, Junqi Liu, Fang Wu · 2021 · Clinical Epigenetics
60. Mechanisms of metastatic colorectal cancer
    Adrià Cañellas-Socias, Elena Sancho, Eduard Batlle · 2024 · Nature Reviews Gastroenterology & Hepatology
61. The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200
    Noman, Muhammad Zaeem, Janji, Bassam, Abdou, Abderemane, Hasmim, Meriem, Terry, Stéphane, Tan, Tuan Zea, Mami-Chouaib, Fathia, Thiery, Jean Paul, Chouaib, Salem · 2017 · OncoImmunology
62. Enhancing Virus-Specific Immunity In Vivo by Combining Therapeutic Vaccination and PD-L1 Blockade in Chronic Hepadnaviral Infection
    Jia Liu, Ejuan Zhang, Zhiyong Ma, Weimin Wu, Anna D. Kosinska, Xiaoyong Zhang, Inga Möller, Pia L. Seiz, Dieter Glebe, Baoju Wang et al. · 2014 · PLoS Pathogens
63. Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point18F-FDG PET/CT Imaging in Patients with Advanced Melanoma
    Steve Y. Cho, Evan J. Lipson, Hyung‐Jun Im, Steven P. Rowe, Esther Mena Gonzalez, Amanda L. Blackford, Alin Chirindel, Drew M. Pardoll, Suzanne Louise Topalian, Richard L. Wahl · 2017 · Journal of Nuclear Medicine
64. Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events
    Elisa González-Rodríguez, Delvys Rodríguez‐Abreu, on behalf of the Spanish Group for Cancer Immuno-Biotherapy (GETICA) · 2016 · The Oncologist
65. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer
    Jin Won Kim, Kyung Han Nam, Sang-Hoon Ahn, Do Joong Park, Hyung‐Ho Kim, Se Hyun Kim, Hyun Kyung Chang, Jeong‐Ok Lee, Yu Jung Kim, Hye Seung Lee et al. · 2014 · Gastric Cancer
66. Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer
    Hwang, Sohyun, Kwon, Ah-Young, Jeong, Ju-Yeon, Kim, Sewha, Kang, Haeyoun, Park, Joonsuk, Kim, Joo-Hang, Han, Ok Jin, Lim, Sun Min, An, Hee Jung · 2020 · Scientific Reports
67. Chemoimmunotherapy: Reengineering Tumor Immunity
    Chen, Gang, Emens, Leisha A. · 2013 · Cancer Immunology, Immunotherapy
68. Checkpoint blocking antibodies in cancer immunotherapy
    Chrisann Kyi, Michael A. Postow · 2013 · FEBS Letters
69. Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment
    Kanstantsin V. Katlinski, Jun Gui, Yuliya V. Katlinskaya, Angélica Ortiz, Riddhita Chakraborty, Sabyasachi Bhattacharya, Christopher J. Carbone, Daniel P. Beiting, Melanie A. Girondo, Amy R. Peck et al. · 2017 · Cancer Cell
70. Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
    Hyun Tae Lee, Ju‐Yeun Lee, Heejin Lim, Sang Hyung Lee, Yu Jeong Moon, Hyo Jeong Pyo, Seong Eon Ryu, Woori Shin, Yong-Seok Heo · 2017 · Scientific Reports
71. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
    Blanca Homet Moreno, Antoni Ribas · 2015 · British Journal of Cancer
72. Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models
    William Karl Decker, Rodrigo Fernandes da Silva, Mayra Hernandez Sanabria, Laura S. Angelo, Fernando Guimarães, Bryan M. Burt, Farrah Kheradmand, Silke Paust · 2017 · Frontiers in Immunology
73. Blockage of Core Fucosylation Reduces Cell-Surface Expression of PD-1 and Promotes Anti-tumor Immune Responses of T Cells
    Masahiro Okada, Shunsuke Chikuma, Taisuke Kondo, Sana Hibino, Hiroaki Machiyama, Tadashi Yokosuka, Miyako Nakano, Akihiko Yoshimura · 2017 · Cell Reports
74. Predictive Markers for the Efficacy of Anti–PD-1/PD-L1 Antibodies in Lung Cancer
    Takehito Shukuya, David Paul Carbone · 2016 · Journal of Thoracic Oncology
75. Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis
    Hui Zhang, Ryu Watanabe, Gerald J. Berry, Augusto Vaglio, Yaping Joyce Liao, Kenneth J. Warrington, Jörg J. Goronzy, Cornelia M. Weyand · 2017 · Proceedings of the National Academy of Sciences
76. Clinical validation of the tempus xT next-generation targeted oncology sequencing assay
    Nike T. Beaubier, Robert W. Tell, Denise Lau, Jerod Parsons, Stephen Bush, Jason F. Perera, Shelly Sorrells, Timothy Baker, Alan Lee Chang, Jackson Michuda et al. · 2019 · Oncotarget
77. Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study
    Thomas S. Uldrick, Priscila Hermont Goncalves, Maher Abdul‐Hay, Alisa J Claeys, Brinda Emu, Marc S. Ernstoff, Steven P. Fling, Lawrence H. Fong, Judith C. Kaiser, Andreanne M. Lacroix et al. · 2019 · JAMA Oncology
78. ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation
    Mengjie Hu, Min Zhou, Xuhui Bao, Dong Pan, Meng Jiao, Xinjian Liu, Fang Li, Chuan‐Yuan Li · 2020 · Journal of Clinical Investigation
79. Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor
    Deepak Mittal, Arabella Young, Kimberley A. Stannard, Michelle C.R. Yong, Michele W.L. Teng, Bertrand Allard, John Stagg, Mark John Smyth · 2014 · Cancer Research
80. Molecular Pathways: Interleukin-15 Signaling in Health and in Cancer
    Anjali Mishra, Laura Sullivan, Michael A. Caligiuri · 2014 · Clinical Cancer Research
81. Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research
    Zachary J. Brown, Bernd Heinrich, Tim F. Greten · 2018 · Nature Reviews Gastroenterology & Hepatology
82. The Immune Microenvironment in Pancreatic Cancer
    Magdalena Huber, Corinna U. Brehm, Thomas Mathias Gress, Malte Buchholz, Bilal Alashkar Alhamwe, Elke Pogge von Strandmann, Emily P. Slater, Jörg Walter Bartsch, Christian Alexander Bauer, Matthias Lauth · 2020 · International Journal of Molecular Sciences
83. iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti–PD-1 therapy
    Frank M. Cichocki, Ryan Bjordahl, Svetlana Gaidarova, Sajid Mahmood, Ramzey Abujarour, Hongbo Wang, Katie Tuininga, Martin Felices, Zachary Davis, Laura E. Bendzick et al. · 2020 · Science Translational Medicine
84. eIF2α phosphorylation is pathognomonic for immunogenic cell death
    Lucillia Bezu, Allan Sauvat, Juliette F Humeau, Lígia Catarina Gomes-da-Silva, Kristina Iribarren, Sabrina Forveille, Pauline Garcia, Liwei Zhao, Peng Liu, Laurence Zitvogel et al. · 2018 · Cell Death and Differentiation
85. Tumoral Expression of IL-33 Inhibits Tumor Growth and Modifies the Tumor Microenvironment through CD8+ T and NK Cells
    Xin Gao, Xuefeng Wang, Qianting Yang, Xin Zhao, Wen Wen, Gang Li, Junfeng Lu, Wenxin Qin, Yuan Qi, Fang Xie et al. · 2014 · The Journal of Immunology
86. Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy
    Stephen J. Blake, Kimberley A. Stannard, Jing Liu, Stacey M. Allen, Michelle C.R. Yong, Deepak Mittal, Amelia Roman Aguilera, John J. Miles, Viviana P. Lutzky, Lucas Ferrari de Andrade et al. · 2016 · Cancer Discovery
87. Genetic and Epigenetic Regulation of PD-1 Expression
    Alexander P. R. Bally, James W Austin, Jeremy M. Boss · 2016 · The Journal of Immunology
88. TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action
    Wenwen Du, Min Yang, Abbey Turner, Chunling Xu, Robert Louis Ferris, Jian‐An Huang, Larry Kane, Binfeng Lu · 2017 · International Journal of Molecular Sciences
89. Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review
    Feifei Teng, Xiangjiao Meng, Li Kong, Jinming Yu · 2017 · Cancer Letters
90. Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions
    Massimo Ralli, Andrea Botticelli, Irene Claudia Visconti, Diletta Angeletti, Marco Fiore, Paolo Marchetti, Alessandro Lambìase, Marco DE VINCENTIIS, Antonio Greco · 2020 · Journal of Immunology Research
91. Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival
    Ludmila Danilova, Won Jin Ho, Qingfeng Zhu, Teena Vithayathil, Ana De Jesus‐Acosta, Nilofer Saba Azad, Daniel A. Laheru, Elana Judith Fertig, Robert A. Anders, Elizabeth M. Jaffee et al. · 2019 · Cancer Immunology Research
92. In vivo discovery of immunotherapy targets in the tumour microenvironment
    Zhou, Penghui, Shaffer, Donald R., Alvarez Arias, Diana A., Nakazaki, Yukoh, Pos, Wouter, Torres, Alexis J., Cremasco, Viviana, Dougan, Stephanie K., Cowley, Glenn S., Elpek, Kutlu et al. · 2014 · Nature
93. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects
    Hongyan Jia, Cristina I. Truica, Bin Wang, Yanhong Wang, Xingcong Ren, Harold A. Harvey, Jianxun Jim Song, Jinming Yang · 2017 · Drug Resistance Updates
94. PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1
    Gang Chen, Yong Ho Kim, Hui Li, Hao Luo, Da-Lu Liu, Zhijun Zhang, Mark Lay, Wonseok Chang, Yu‐Qiu Zhang, Ru‐Rong Ji · 2017 · Nature Neuroscience
95. Cancer immunotherapy: broadening the scope of targetable tumours
    Jitske van den Bulk, Els M.E. Verdegaal, Noel F.C.C. de Miranda · 2018 · Open Biology
96. Immune checkpoints in the tumor microenvironment
    Salman M. Toor, Varun Sasidharan Nair, Julie V. Decock, Eyad Elkord · 2019 · Seminars in Cancer Biology
97. Cancer mRNA vaccines: clinical advances and future opportunities
    Elias Joseph Sayour, David Boczkowski, Duane A. Mitchell, Smita K. Nair · 2024 · Nature Reviews Clinical Oncology
98. The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck
    Dan Paul Zandberg, Scott Eric Strome · 2014 · Oral Oncology
99. The new normal: immunomodulatory agents against sepsis immune suppression
    Noelle A. Hutchins, Jacqueline Unsinger, Richard S. Hotchkiss, Alfred Ayala · 2014 · Trends in Molecular Medicine
100. Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer
     Yoon Young Choi, Hyunki Kim, Su‐Jin Shin, Ha Yan Kim, Jinae Lee, Han‐Kwang Yang, Woo Ho Kim, Young‐Woo Kim, Myeong‐Cherl Kook, Young Kyu Park et al. · 2018 · Annals of Surgery